Stock Ratings / Health Care / MRVI / insiders

VERA (35) PRGO (41) PVLA (46) XNCR (43) ⌘ Pro Terminal →

Maravai LifeSciences Holdings Inc. (Class A) (MRVI) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$8.46 -0.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Maravai LifeSciences Holdings Inc. (Class A) (MRVI) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRVI)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

MRVI Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (MRVI)

No recent open-market Form 4 cluster sales or emergency dumps flagged on MRVI. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRVI)

✓Walkthrough of MRVI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MRVI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +129.89%▲ RESISTANCE BREAKOUT

2026-10-30O $8.34H $8.48L $7.68C $8.46VOL 1.70M

RES: $8.30SUP: $6.56SMA50: $7.50SMA200: $5.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRVI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MRVI Butterfly Map → + Track MRVI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -28.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MRVI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MRVI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MRVI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRVI)

Health Care Rank #773 of 1016 ⚔️ VERA vs MRVI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MRVI vs. VERA, PRGO, PVLA, XNCR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Maravai LifeSciences Holdings Inc. (Class A) (MRVI) ranks #773 by composite RQD confidence (36/100, grade D-) and #246 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, MRVI leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. PVLA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MRVI at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MRVI ACTIVE Maravai LifeSciences Holdings Inc. (Class A)	D-	36/100	—	18.3%	-35.0%	-0.47%	$2.20B	Benchmark Subject
VERA Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	/vera-vs-mrvi →
PRGO Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	/prgo-vs-mrvi →
PVLA Palvella Therapeutics Inc.	D	46/100	—	—	-27.9%	+2.79%	$2.18B	/pvla-vs-mrvi →
XNCR Xencor Inc.	D-	43/100	—	—	-21.3%	-2.60%	$2.17B	/xncr-vs-mrvi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001823239

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Maravai LifeSciences Holdings Inc. (Class A) (MRVI) reported GAAP revenue of $185.7M (-28.3% vs. FY2024 revenue of $259.2M , and -35.7% cumulative change since FY2023) , GAAP net income of -$130.8M, operating cash flow of -$57.6M, and free cash flow of -$70.7M (-218.7% YoY). On the balance sheet, MRVI closed FY2025 with $770.6M in total assets against $286.3M in total debt (Altman Z-Score: 3.04, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$185.7M	-$130.8M	-$57.6M	-$70.7M	$770.6M	$286.3M
FY2024 (FY)	2024-12-31	$259.2M	-$144.8M	$7.5M	-$22.2M	$1.01B	$290.5M
FY2023 (FY)	2023-12-31	$288.9M	-$138.4M	$126.2M	$126.2M	—	—

3. MRVI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ: MRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $8.46 (-0.47% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MRVI ranks #773 in composite RQD confidence.

How does MRVI compare to VERA and PRGO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRVI carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 18.3%, and ROIC of -35.0%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and PRGO (Perrigo Company plc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -13.6%, cap $2.21B). Among the 5-stock peer group, MRVI leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MRVI?

Per MRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001823239), Maravai LifeSciences Holdings Inc. (Class A) generated $185.7M in revenue (-28.3% YoY), -$130.8M in net income, and -$70.7M in free cash flow against $770.6M in total assets and $286.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MRVI trading relative to its 50-day, 200-day, and 52-week technical levels?

MRVI last traded at $8.46 (-0.47% on volume of 1,385,362 shares), positioning the stock +12.80% above its 50-day simple moving average ($7.50) and +61.45% above its 200-day simple moving average ($5.24). Across its 52-week range of $2.55 to $9.42, MRVI sits at the 86.0% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.40 to $9.52).

MRVI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are MRVI insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies MRVI leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: MRVI RQD Cockpit MRVI 12M Forecast MRVI Earnings & Move MRVI Dividends & DRIP MRVI Insiders & 13F MRVI Whale Options MRVI Profit Sankey MRVI News & Why